Table 1.
Demographic and clinical characteristics of children with ALL/NHML and MTX treatment toxicity
| Characteristic | ALL patients |
|---|---|
| (N = 88) | |
| Gender (%) | |
| Male | 41 (46.6) |
| Female | 47 (53.4) |
| Median age at diagnosis, years (range) | 4.58 (0.3–16.6) |
| Median body surface area, m2 (range) | 0.73 (0.4–1.9) |
| Leukaemia subtype (%); | |
| B-cell | 72 (81.8) |
| T-cell | 13 (14.7) |
| Undetermined | 3 (3.4) |
| Median No. leukocytes at diagnosis, 109 cells/L (range) | 9.35 (1–1650) |
| Median No. thrombocytes at diagnosis, 109 cells/L (range) | 72 (3–553) |
| Median haemoglobin conc., g/l (range) | 84 (43–148) |
| Median % of blasts at diagnosis (range) | 23.5 (0–97) |
| Median MTX dose, mg (range) | 3300 (540–9200) |
| MTX response | Present, N (%) |
| Relapse | 8 (9.2)** |
| Exitus | 4 (4.6)** |
| All MTX-induced ADEs* | 48 (54.5) |
| Leukopenia | 33 (37.5) |
| Thrombocytopenia | 16 (18.2) |
| Mucositis | 15 (17.0) |
| Neurotoxicity | 7 (8.0)** |
**
data is missing for one patient
*
data was collected after the first cycle of MTX